Summary
This Form 8-K filing by Amgen Inc. (AMGN) on April 20, 2011, primarily serves to report the company's unaudited financial results for the first quarter ended March 31, 2011, and its financial position as of that date, as detailed in an accompanying press release (Exhibit 99.1). The report emphasizes Amgen's use of non-GAAP financial measures, which exclude various items such as stock option expensing, acquisition-related costs and amortization, manufacturing asset adjustments, and other specific charges. The company states these non-GAAP measures are presented to provide supplementary information and facilitate additional analysis by investors, enabling comparisons across periods by excluding certain non-recurring or accounting-specific impacts. Investors should note that Amgen provides detailed reconciliations between its GAAP and non-GAAP figures in the referenced press release. Key adjustments made for the first quarter of 2011 include excluding costs related to acquisitions (Avidia, Abgenix, Immunex, BioVex), manufacturing transactions (BI Fremont), and ongoing cost efficiency initiatives. The company also highlights adjustments for non-cash interest expense related to convertible notes and the tax effects of these adjustments. The focus on non-GAAP reporting indicates Amgen's strategy to present a clearer operational view, potentially smoothing out the impact of significant corporate activities and accounting treatments on its reported earnings and financial condition.
Key Highlights
- 1Amgen Inc. filed an 8-K on April 20, 2011, to report its unaudited Q1 2011 financial results and financial position as of March 31, 2011.
- 2The filing incorporates a press release (Exhibit 99.1) containing detailed financial information for the three months ended March 31, 2011, and comparative periods.
- 3Amgen extensively utilizes non-GAAP financial measures to present its results, aiming to provide supplemental insights for investors.
- 4Key non-GAAP adjustments include excluding stock option expensing, amortization of acquired intangibles (from acquisitions like Immunex, Abgenix, Avidia), and acquisition/transaction-related costs.
- 5The report details adjustments for manufacturing-related charges (BI Fremont Transaction Accelerated Depreciation, Lease Loss Accruals) and cost-saving initiatives.
- 6Non-cash interest expense related to convertible notes and the tax effects of various adjustments are also excluded in non-GAAP reporting.
- 7The company presents a non-GAAP effective tax rate that excludes the impact of Puerto Rico excise tax.